Daniel Choi, MD
Ophthalmology · Stockton, CANPI 1801164827
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,400 of the $8,786 with a category attached, or 61.5%. 24 manufacturers reported payments, led by Rxsight Inc at 56.5% of the total. 2025 is the largest year on record at $5,422, 9.2 times the $589 reported in 2019.
Across 150 payments — averaging $58.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$5K
- AbbVie$921
- Glaukos Corporation$825
- Alcon$584
- Aerie Pharmaceuticals, Inc.$297
- Johnson & Johnson$207
- plus $987 from 18 others
Across 48 payments — averaging $71.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Argenx US, Inc.$3K
What the payments were for
- Consulting fees$5,40061%
- Food & beverage$3,33238%
- Education$370%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 12 | $4,965 |
| AbbVie(2 entities) | 65 | $921 |
| Glaukos Corporation | 1 | $825 |
| Alcon | 19 | $584 |
| Aerie Pharmaceuticals, Inc. | 20 | $297 |
| Johnson & Johnson | 3 | $207 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $130 |
| Dompe US, Inc. | 1 | $100 |
| Nova Eye, Inc. | 1 | $94 |
| Novo Nordisk | 1 | $88 |
| Sight Sciences, Inc. | 3 | $88 |
| Thea Pharma Inc. | 4 | $87 |
| Novartis | 3 | $69 |
| Bausch & Lomb Americas Inc. | 3 | $51 |
| Rayner Intraocular Lenses Limited | 1 | $46 |
| Optos, Inc. | 2 | $41 |
| Biotissue Holdings Inc. | 2 | $40 |
| Ocular Therapeutix, Inc. | 2 | $39 |
| Oyster Point Pharma, Inc. | 1 | $26 |
| Amgen | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| NEW World Medical,inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$4,752
- RXSIGHT INJECTOR CARTRIDGE$4,752
- RXSIGHT INJECTOR HANDPIECE$4,752
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$4,752
- LIGHT ADJUSTABLE LENS (LAL)$4,752
- KXL System$825
- TRIALTIS$148
- CATALYS SYSTEM$130
- Rhopressa$109
- Rocklatan$109
- Unity$104
- Oxervate$100
How this compares
$8,786 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 655 | $297,764 |
| LumiganBimatoprost | 413 | $201,221 |
| RestasisCyclosporine | 83 | $80,984 |
| Latanoprost | 3,187 | $49,711 |
| RocklatanNetarsudil Mesylat/Latanoprost | 100 | $43,067 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 195 | $38,382 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,767 | $35,741 |
| Brimonidine Tartrate | 1,393 | $35,539 |
| CombiganBrimonidine Tartrate/Timolol | 81 | $35,321 |
| Prednisolone Acetate | 976 | $32,074 |
| Alphagan PBrimonidine Tartrate | 61 | $25,003 |
| VyzultaLatanoprostene Bunod | 64 | $23,545 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 60 | $18,999 |
| TafluprostTafluprost/Pf | 92 | $16,438 |
| Cyclosporine | 18 | $14,228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $921 | $342,528638 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $297 | $340,831755 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $51 | $23,54564 claims |
| AlconSimbrinza | $584 | $18,99960 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Stockton
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.